Colchicine, a widely used drug for the prevention and treatment of gout flares, interacts dangerously with many commonly prescribed pharmaceuticals, such as antibiotics, anti-hypertensive drugs, anti-fungals, immunosuppresants and protease inhibitors, according to a study published in the August issue of Arthritis & Rheumatism. However, most patients can take colchicines safely with these medications as long as the dose is adjusted, the study indicated.
Colchicine, a widely used drug for the prevention and treatment of gout flares, interacts dangerously with many commonly prescribed pharmaceuticals, such as antibiotics, antihypertensive drugs, antifungals, immunosuppressants, and protease inhibitors, according to a study published in the August issue of Arthritis & Rheumatism. However, most patients can take colchicines safely with these medications as long as the dose is adjusted, the study indicated.
To develop evidence-based colchicine-dosing algorithms with improved safety, a series of drug-drug interaction (DDI) studies was performed to assess the concomitant treatment of colchicine with known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER).
In all, there were 7 studies. All were open-label, non-randomized, single-center, 1-sequence, 2-period DDI experiments, using two 0.6-mg doses of colchicine, separated by a minimum 14-day washout period, followed by administration of the approved on-label regimen of known CYP3A4/P-glycoprotein inhibitors.
Each of the drugs, except for azithromycin, was found to interact significantly with standard colchicine dosing regimens; in some cases more than doubling levels of colchicine in the blood and increasing the risk of serious toxicities. Cyclosporine and clarithromycin in particular increased peak colchicine blood levels by nearly 300%.
The authors recommended that colchicine doses be reduced between of 33% to 66% for the treatment of acute gout and 50% to 75% for prophylaxis, when used as concomitant therapy with each of the drugs studied with the exception of azithromycyin where no dose adjustments were necessary.
Specific dosing recommendations resulting from the study are as follows:
Drug
Acute Flare Dosing Recommendations
Flare Prophylaxis Dosing Recommendations
Familial Mediterranean Fever Dosing Recommendations
cyclosporine
0.6 mg (1 tablet) X 1 dose
0.3 mg once a day, or 0.3 mg every other day
Maximum daily dose of 0.6 mg (or 0.3 mg twice a day)
clarithromycin, ketoconazole, ritonavir
0.6 mg (1 tablet) X 1 dose, followed by 0.3 mg (half tablet) 1 hour later
0.3 mg once a day, or 0.3 mg every other day
Maximum daily dose of 0.6 mg (or 0.3 mg twice a day)
diltiazem, verapamil
1.2 mg (2 tablets) X 1 dose
0.3 mg twice a day (or 0.6 mg once a day), or 0.3 mg once a day
Maximum daily dose of 1.2 mg (or 0.6 mg twice a day)
azithromycin
No dose reduction required
No dose reduction required
No dose reduction required
The studies were among the 17 clinical trials conducted by URL Pharma that led to FDA approval of Colcrys.
“Despite the fact that colchicine has been used for decades in the prevention and treatment of gout flares and for FMF, the pharmacokinetics and metabolism of colchicine have not been extensively studied, until now,” said Robert A. Terkeltaub, MD, interim division chief and professor of medicine at the University of California San Diego and the VA Medical Center, and the paper’s lead author. “The results of these studies form the foundation of evidence-based dosing guidance for colchicine in the presence of CYP3A4 or P-gp inhibitors that help achieve optimal therapeutic benefit while avoiding dangerous and unnecessary safety risks.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.